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NeurodegenerationCLN7 is a polytopic lysosomal membrane glycoprotein of unknown function and is deﬁcient in variant late
infantile neuronal ceroid lipofuscinosis. Here we show that full-length CLN7 is proteolytically cleaved
twice, once proximal to the used N-glycosylation sites in lumenal loop L9 and once distal to these sites. Cleav-
age occurs by cysteine proteases in acidic compartments and disruption of lysosomal targeting of CLN7 re-
sults in inhibition of proteolytic cleavage. The apparent molecular masses of the CLN7 fragments suggest
that both cleavage sites are located within lumenal loop L9. The known disease-causing mutations,
p.T294K and p.P412L, localized in lumenal loops L7 and L9, respectively, did not interfere with correct lyso-
somal targeting of CLN7 but enhanced its proteolytic cleavage in lysosomes. Incubation of cells with selective
cysteine protease inhibitors and expression of CLN7 in gene-targeted mouse embryonic ﬁbroblasts revealed
that cathepsin L is required for one of the two proteolytic cleavage events. Our ﬁndings suggest that CLN7 is
inactivated by proteolytic cleavage and that enhanced CLN7 proteolysis caused by missense mutations in se-
lected luminal loops is associated with disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Lysosomal membrane proteins have numerous functions including
acidiﬁcation of the lysosomal lumen, mediating fusion with other or-
ganelles, self-protection against proteolytic digestion, export of degra-
dation products into the cytosol, protein import from the cytosol and
motion of organelles [1]. The precise functions, however, of themajority
of the lysosomal membrane proteins are unknown [2,3]. Defects in
genes encoding lysosomal membrane proteins have been linked to a
growing number of lysosomal storage disorders [4]. The neuronal
ceroid lipofuscinoses (NCL) represent a group of lysosomal storage dis-
eases which are characterized by the accumulation of lipofuscin-like
ceroid lipopigments and the selective damage and loss of neurons [5].
NCL-causing mutations have been identiﬁed in eleven different genes
encoding the soluble cysteine-string protein alpha (CLN4/DNAJC5),e; Ctsb, cathepsin B; Ctsl, ca-
; endo H, endoglycosidase H;
in; HEK293, human embryonic
saminide N-acetyltransferase;
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9 40 7410 58504.
ch).
rights reserved.soluble lysosomal proteins (CLN1/palmitoyl-protein thioesterase 1,
CLN2/tripeptidyl peptidase I, CLN5 and CLN10/cathepsin D), lysosomal
membrane proteins (CLN3, CLN7/MFSD8, CLN12/ATP13A2 and ClC-7)
and polytopic membrane proteins localized in the endoplasmic reticu-
lum (CLN6 and CLN8) [5–8]. CLN7 disease, late infantile variant pheno-
type (MIM# 610951) is caused by defects in the CLN7/MFSD8 genewith
31 differentmutations known to date [9–14]. The CLN7/MFSD8 gene en-
codes a polytopic lysosomal membrane protein of unknown function
with 12 transmembrane domains, cytosolic N and C termini and two
conﬁrmed N-glycosylation sites in positions N371 and N376 [15]. The
CLN7/MFSD8 gene product is localized in lysosomes in non-neuronal
and neuronal cells [9,15,16]. Its lysosomal targeting along the indirect
pathway via the plasma membrane is mediated by an N-terminal
dileucine-based E9 QEP L13L14 sorting signal [15]. CLN7 is a member of
the major facilitator superfamily (MFS) of transporter proteins which
are capable of transporting a wide range of low-molecular-mass sub-
strates including carbohydrates and amino acids [17]. CLN7 is therefore
believed to be a lysosomal transporter, but its substrate has not been
identiﬁed.
We have previously shown that the intensity of CLN7-GFP immuno-
reactive bands increased after inhibiting cysteine and aspartic proteases
[15]. In the present study we describe the proteolytic cleavage of the
CLN7 membrane protein in endosomal/lysosomal compartments.
CLN7 is asymmetrically cleaved twice in a cell-type independent man-
ner. Inhibitor studies and expression analyses in gene-targeted mouse
embryonic ﬁbroblasts (MEF) demonstrated that the cysteine protease
cathepsin L (Ctsl) is required for one of the two proteolytic cleavage
1618 P. Steenhuis et al. / Biochimica et Biophysica Acta 1822 (2012) 1617–1628events. In addition, two missense mutations identiﬁed in patients with
CLN7 disease, p.T294K and p.P412L, resulted in increased proteolytic
cleavage of CLN7 in lysosomes.
2. Materials and methods
2.1. Antibodies and reagents
The following antibodies were used forWestern blot analyses: mouse
anti-GFP (1:500 dilution; Roche Applied Science, Mannheim, Germany),
mouse anti-FLAG (cloneM2, 1:1000 dilution; Sigma-Aldrich, Taufkirchen,
Germany), andmouse anti-Myc (clone 9B11, 1:1000 dilution; Cell Signal-
ing Technologies, Danvers,MA). Antibodies used for immunoﬂuorescence
microscopy were as follows: polyclonal anti-human cathepsin D (1:100
dilution, [18]), monoclonal anti-human LAMP-1 (clone H4A3, 1:150 dilu-
tion; Developmental Studies Hybridoma Bank, Iowa City, IA), polyclonal
anti-Myc (1:100 dilution; Sigma-Aldrich), monoclonal anti-FLAG (clone
M2, 1:100 dilution) and polyclonal anti-FLAG (1:100 dilution, Sigma-
Aldrich). Secondary goat anti-mouse antibodies coupled to horse radish
peroxidase were from Dianova (Hamburg, Germany) and were used at
a 1:5000 dilution. Fluorochrome-coupled secondary antibodies goat
anti-rabbit IgG AlexaFluor 488, goat anti-rabbit IgG Cy5, goat anti-rabbit
IgG AlexaFluor 546, goat anti-mouse IgG AlexaFluor 488 and goat anti-
mouse IgG AlexaFluor 546 were from Invitrogen (Karlsruhe, Germany)
and used at a 1:1000 dilution.
The following reagents were obtained commercially as indicated:
Normocin from Invivogen (SanDiego, CA), fast digest restriction enzymes
from Fermentas (St. Leon-Rot, Germany), Quick Start Bradford Protein
Assay fromBio-Rad (Munich, Germany), peptideN-glycosidase F (PNGase
F) from Roche Applied Sciences (Mannheim, Germany), endoglycosidase
H (endoH) fromNewEngland Biolabs (Ipswich,MA), Pfu Turbo polymer-
ase and QuikChange site-directed mutagenesis kit from Stratagene
Europe (Amsterdam, the Netherlands), Dulbecco's minimal essential
medium (DMEM), fetal calf serum, Glutamax, penicillin, streptomycin,
trypsin/EDTA, Lipofectamine 2000 and Optimem from Invitrogen,
Phusion® High-Fidelity DNA polymerase from Finnzymes (Espoo,
Finland), GeneJETTM Plasmid Mini Kit and gel extraction kit from
Fermentas (St. Leon-Rot, Germany), Plasmid Midi Kit from QIAGEN
(Hilden, Germany), medium for cultivating Escherichia coli from Roth
(Karlsruhe, Germany), prestained Rainbow marker, and ultrapure
dNTPs fromGEHealthcare Life Sciences (Freiburg, Germany). Oligonucle-
otides used for cloning and sequencing were synthesized by MWG
Biotech (Munich, Germany). Cycloheximide, brefeldin A, leupeptin,
pepstatin A, E-64, SID26681509, and protease inhibitor cocktail were
purchased from Sigma-Aldrich, Ctsl inhibitor Z-FY-CHO from Calbiochem
(Nottingham, UK), Albumin standard and enhanced chemiluminescence
reagents fromThermoFisher Scientiﬁc (Rockford, IL). GFP-TRAP®agarose
beads were purchased from ChromoTek (Planegg-Martinsried,
Germany).
2.2. Plasmids and transgenic cDNA constructs
The generation of the GFP-CLN7 cDNA construct has been described
previously [15]. A cDNA construct with a triple FLAG tag fused to the N-
terminus of CLN7 was generated by amplifying the cDNA coding for
human CLN7 (NM_152778, RZPD clone IRATp970E0532D6; imaGenes,
Berlin, Germany) by PCR using primers 3xFLAG pCMV10-CLN7 F/R and
by cloning the resulting PCR product into HindIII and BamHI sites of ex-
pression vector p3xFLAG-CMV10 (Sigma-Aldrich). The pcDNA3.1 (+)
CLN7-3xMyc cDNA construct was generated by amplifying a PCR product
with primers pcDNA3.1. (+) CLN7-3xMyc F/R using GFP-CLN7 as a DNA
template. The resulting PCR product was subcloned into the pCR®-
BluntII-TOPO® vector (Invitrogen), the fragment subsequently excised
with restriction enzymes HindIII and BamHI and cloned into the
corresponding sites of expression vector pcDNA3.1 Hygro (+)-3xMyc
[19]. The GFP-CLN7-3xMyc expression construct was generated byamplifying a PCR product with primers pcDNA3.1 GFP-CLN7 3xMyc F/R
using the GFP-CLN7 cDNA as template. The PCR product was cloned
into pcDNA3.1D/V5-His-TOPO® vector (Invitrogen). For the cloning
of the 3xFLAG-mucolipin-1 construct a cDNA clone (IMAGE clone
p998L049490Q) containing the human mucolipin-1 cDNA (NM_02
0533) was ampliﬁed by PCR with primers 3xFLAG pCMV10-
mucolipin-1F/R. The resulting PCR product was subcloned into the
pCR®-BluntII-TOPO® vector and recombinant vectors were subse-
quently incubated with restriction enzymes HindIII and SacI. The
fragment was ﬁnally cloned into the HindIII/SacI sites of vector
pCMV10 3xFLAG (Sigma).
All primers used for cloning and site-directed mutagenesis are
described in the Supplementary material (Table S1). Mutagenesis
was performed using the QuikChange® site-directed mutagenesis kit.
All constructs were sequenced by Seqlab (Göttingen, Germany). The
cDNAs encoding mouse cathepsin L (Ctsl, NM_009984) and cathepsin
B (Ctsb, NM_007798) cloned into expression vector pcDNA3.1 (+)
were kindly provided by Dr. Schröder (University of Kiel, Germany).
2.3. Cell culture and transfections
COS-7, HEK293 cells, wild-type and Ctsl(−/−)- and Ctsb(−/−)
mouse embryonic ﬁbroblasts (MEF) were cultivated in DMEM con-
taining 10% fetal calf serum, 1× Glutamax, 100 μg/ml Normocin,
100 IU/ml penicillin, and 50 mg/ml streptomycin. Ctsb(−/−) and
Ctsl(−/−) MEF were described previously [20,21]. Cells were trans-
fected with Lipofectamine 2000 (Invitrogen) and Optimem according
to the manufacturers' instructions and cells were analyzed 24 h after
the start of transfection. Where indicated, media were supplemented
with brefeldin A (BFA) or protease inhibitors during the complete
course of transfection.
2.4. Western blotting
Cells grown on 35 mm dishes were scraped in ice-cold phosphate-
buffered saline, pH 7.4, and centrifuged for 5 min at 1000×g. Cell pellets
were lysed in 100 μl ice-cold lysis buffer (10 mM Tris pH 7.5, 150 mM
NaCl, 5 mM EDTA, 0.1% SDS, 1% TX-100, 1% sodium deoxycholate) sup-
plemented with protease inhibitors. After incubation for 30 min on ice,
extracts were centrifuged at 15,000×g for 10 min followed by determi-
nation of protein concentrations with a Bradford assay. Aliquots of total
cell extracts were solubilized in Laemmli sample buffer containing 1%
beta-mercaptoethanol at 50 °C for 10 min. Samples were separated by
SDS-PAGE (10% acrylamide unless otherwise speciﬁed). Proteins
were transferred to PVDF membranes (GE Healthcare, Munich, Ger-
many). ECL-detection was performed using the manufacturer's in-
structions (Thermo Fisher Scientiﬁc) and blots were imaged on a
Molecular Imager (Model Chemi Doc XRS, Bio-Rad). For complete
removal of all N-linked oligosaccharides from CLN7 50 μg of total
cell extracts was denatured for 10 min at 50 °C in 0.3% SDS and
protease inhibitors, followed by the addition of NP-40 (ﬁnal con-
centration: 1%) and 3 units PNGase F. For removal of N-linked
high-mannose and hybrid oligosaccharides 50 μg of total cell ex-
tracts was denatured in denaturation buffer (New England Biolabs)
for 10 min at 50 °C, followed by the addition of buffer G5 and 1000
units endo H. Samples were incubated in the presence of endo H or
PNGase at 37 °C for 30 to 60 min, followed by analysis by SDS-PAGE
and immunoblotting.
2.5. Co-immunoprecipitations
HEK293 cells were co-transfected with GFP-CLN7 and 3xFLAG-CLN7
or GFP-CLN7 and CLN7-3xMyc and harvested 24 h after the start of trans-
fection. Cell pellets were lysed using 200 μl of a low-detergent lysis buffer
(10 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP40, protease
inhibitors) to leave protein complexes intact. Subsequently, GFP-CLN7
1cytosol
lumen
2 3 54 6 7 8 9 10
L1
L2
L3
L4
L5
L6
L7
L8
L9
L10
L11
2.
CLN7
3x
Myc
1.
3x
FLAG CLN7
NH2
COOH
3.
CLN7
3x
MycGFP
A
B
Fig. 1. Schematic representation of CLN7 membrane topology and used cDNA con-
structs. (A) Predicted topology model of the CLN7 membrane protein indicating orien-
tation of the N- and C-terminal domains, loops L1-L11, the transmembrane domains
1–12, and the two used N-glycosylation sites at positions 371 and 376. (B) Schematic
representation of the used CLN7 cDNA constructs with positions of the epitope tags.
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dilution buffer (10 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, protease
inhibitors), pre-clearedwith empty agarose beads for 1 h at 4 °C and sub-
sequently incubatedwith GFP-TRAP® agarose beads for 2 h at 4 °C. Beads
werewashed oncewith 500 μl dilution bufferwithout protease inhibitors
and co-precipitated 3xFLAG-CLN7 and CLN7-3xMyc were eluted in
Laemmli sample buffer containing 1% beta-mercaptoethanol at 50 °C for
10 min. To conﬁrm successful immunoprecipitation, GFP-CLN7 was elut-
ed froma small fraction (10%) of the beads in Laemmli sample buffer con-
taining 1% beta-mercaptoethanol at 95 °C for 10 min. The eluted fractions
were analyzed by Western blotting.
2.6. Cycloheximide pulse-chase analysis
COS-7 cells were transiently transfected for 24 h and were either
harvested (pulse) or incubated in the presence of 100 μg/ml cyclohexi-
mide (CHX) to stop new protein synthesis for the indicated time inter-
vals. Total cell extracts were analyzed by SDS-PAGE and anti-FLAG
immunoblotting.
2.7. Immunoﬂuorescence confocal microscopy
Cells grown on glass cover slipswere transfected and incubatedwith
CHX (100 μg/ml) for 4 h prior to ﬁxation. Cells were ﬁxed in 4% parafor-
maldehyde and permeabilized with 10 mM phosphate-buffered saline,
pH 7.4 containing 0.1% saponin as previously described [15]. After incu-
bation with primary and ﬂuorochrome-conjugated secondary anti-
bodies, cover slips were sealed in mounting medium (DAKO, Glostrup,
Denmark). Cells were analyzed using confocal laser scanningmicrosco-
py (Leica Model TCS-SL, Wetzlar, Germany) and images were merged
using Adobe Photoshop software (Adobe Systems). In experiments
using the polyclonal anti-FLAG antibody cells were ﬁxedwithmethanol
for 5 min at –20 °C followed by a 30-second incubationwith acetone on
ice. Cells were washed with phosphate-buffered saline and blocked
with phosphate-buffered saline containing 1% BSA (PBS/BSA). Primary
and secondary antibodies were diluted in PBS/BSA and the cover slips
were processed as described above.
3. Results
3.1. The CLN7 membrane glycoprotein is proteolytically cleaved by cyste-
ine proteases in acidic compartments
We previously showed that both CLN7 tagged N-terminally with
green ﬂuorescent protein (GFP-CLN7) and CLN7 tagged C-terminally
with GFP (CLN7-GFP) are correctly sorted to lysosomes [15]. However,
it was difﬁcult to detect CLN7-GFP by Western blot analysis suggesting
that the C-terminal domain of CLN7 is unstable. The intensity of the
CLN7-GFP immunoreactive bands could be increased by the treatment
of cells with a combination of cysteine and aspartic protease inhibitors
suggesting proteolysis of the fusion protein in lysosomes.
To analyze proteolytic cleavage of CLN7 in detail, COS-7 cells were
transiently transfected with a cDNA construct encoding CLN7 with an
N-terminally appended triple FLAG tag (3xFLAG-CLN7, Fig. 1) allowing
more-sensitive detection by immunoblotting (Fig. 2A). Western blot
analyses of total cell extracts revealed a prominent immunoreactive
band with apparent molecular masses ranging from 55 to 90 kDa
(Fig. 2A, lane 2, open arrowhead) representing the heterogeneously
N-glycosylated full-length CLN7 protein [15]. In addition, two speciﬁc
immunoreactive bands at 57 and 53 kDa (arrows 1 and 2) and a
36 kDa immunoreactive band corresponding to anN-terminal fragment
of CLN7 were observed (Fig. 2A, closed arrowhead). The 36 kDa band
completely disappeared after raising the pH in endosomes and lyso-
somes with ammonium chloride (Fig. 2A, lane 3; also shown for
HEK293 cells in Supplementary material, Fig. S1A, lane 2). This suggeststhat the 36 kDa CLN7 fragment is generated by proteolytic cleavage in
acidic organelles. Furthermore, treatment of cells with the cysteine pro-
tease inhibitor E-64 [22] or the cysteine/serine protease inhibitor
leupeptin [23] resulted in an increased intensity of the 55–90 kDa
band accompanied by a strong reduction of the 36 kDa band (Fig. 2A,
lanes 4 and 5; shown for HEK293 cells in Supplementary material,
Fig. S1A, lanes 3 and 4). This indicated that cysteine proteases are in-
volved in the cleavage of CLN7. In contrast, incubation of cells with
the aspartic protease inhibitor pepstatin A did not alter the intensi-
ties of either the 55–90 kDa or the 36 kDa bands (Fig. 2A, lanes 6 and
7; shown for HEK293 cells in Supplementary material, Fig. S1A,
lanes 5 and 6).
We have previously shown that CLN7 contains two used N-
glycosylation sites in positions N371 and N376 [15]. To distinguish
endoplasmic reticulum (ER) and cis-Golgi forms from medial- and post
medial-Golgi forms of CLN7, COS-7 cells were transfected with 3xFLAG-
CLN7 and total cell extracts were incubated in the absence or presence of
endo H or PNGase F (Fig. 2B). After endo H treatment the electrophoretic
mobilities of full-length CLN7 (55–90 kDa, open arrowhead) were
unchanged indicating that both N-glycosylation sites contain complex-
type oligosaccharides (Fig. 2B, lanes 2–4). The 57 kDa CLN7 form dis-
appeared upon endo H treatment (Fig. 2B, lanes 2 and 3, arrow 1) accom-
panied by an increase in the intensity of the 53 kDa form (lanes 2 and 3,
arrow 2) indicating that it represents the fraction of CLN7 containing
high-mannose and hybrid N-linked oligosaccharides in the ER and cis-
Golgi apparatus. As expected, PNGase F treatment resulted in the disap-
pearance of the 55–90 kDa full-length CLN7 and the appearance of the
53 kDa form (Fig. 2B, lane 4). The results suggest that the heterogeneous
band pattern of full-length CLN7 is due to the presence of complex N-
linked oligosaccharide chains and conﬁrms our earlier observations [15].
Furthermore, electrophoretic mobility of the 36 kDa N-terminal fragment
(closed arrowhead) was not altered by PNGase F treatment. These results
suggest that the 53 kDa band represents the non N-glycosylated CLN7
backbone protein and that the 36 kDaN-terminal CLN7 fragment contains
no N-linked oligosaccharides. PNGase F treatment of cell extracts also
resulted in the appearance of two additional bandswithmolecularmasses
of 47 and 38 kDa (Fig. 2B, lane 4, arrows 3 and 4). After endo H treatment
no 38 kDa band could be detected indicating that this fragment is endo H-
resistant and thus contains complex-type oligosaccharides (Fig. 2B, lanes 2
and 3).
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Fig. 2. The CLN7 membrane glycoprotein is proteolytically cleaved by cysteine proteases in acidic compartments. (A) COS-7 cells were mock-transfected (lane 1) or transfected with
3xFLAG-CLN7 cDNA and were incubated in the absence (-) or presence (+) of NH4Cl (10 mM, lane 3), cysteine protease inhibitor E-64 (10 μg/ml, lane 4), cysteine/serine protease
inhibitor leupeptin (Leu; 100 μM, lane 5), solvent control (DMSO, lane 6), or aspartic protease inhibitor pepstatin A (Pep A, 100 μM, lane 7) for 24 h. Total cell extracts (50 μg) were
separated by SDS-PAGE and analyzed by FLAG immunoblotting. (B) Total cell extracts (50 μg) from COS-7 cells expressing 3xFLAG-CLN7 were incubated in the absence (-; lane 1) or
presence of endo H (lanes 2 and 3) or peptide N-glycosidase F (PNGase F; lane 4) for the indicated time periods and analyzed by FLAG immunoblotting. (C) COS-7 cells were trans-
fected and treated with inhibitors as described for Fig. 2A and total cell extracts (50 μg) were treated with PNGase F and analyzed by FLAG Western blotting. (D) COS-7 cells were
mock-transfected (lane 1), transfected with wild-type 3xFLAG-CLN7 or 3xFLAG-CLN7 N371/376Q cDNA and treated with NH4Cl (10 mM; lanes 4 and 9) or the cathepsin L inhibitor
Z-FY-CHO (CHO, 10 μM, lanes 6 and 11). Subsequently total cell extracts (50 μg) were incubated with PNGase F and analyzed by FLAG immunoblotting. (E) COS-7 cells were mock-
transfected (lane 1) or transfected with CLN7-3xMyc (lanes 2–4) and were incubated in the absence (-) or presence (+) of NH4Cl (10 mM, lane 4). Total cell extracts (50 μg) were
incubated with PNGase F (lanes 3 and 4) and analyzed by Myc immunoblotting. Positions of the full-length CLN7 (open arrowhead), the 20 kDa C-terminal fragment (closed ar-
rowhead) and the 18 kDa C-terminal fragment (arrow 5) are indicated. (F) COS-7 cells were mock-transfected (lane 1) or transfected with wild-type 3xFLAG-CLN7 (Wt) or
3xFLAG-CLN7 E9A L13A L14A (ELL) and incubated in the absence (-, lanes 1–2 and 5–6) or presence (+; lanes 3 and 4) of brefeldin A (BFA). Cells were harvested and total cell
extracts (50 μg) were incubated with control buffer (-; lanes 1–3 and lane 5) or PNGase F (+; lanes 4 and 6) and analyzed by FLAG immunoblotting. Panels A, B, C, D and F:
The positions of full-length CLN7 (open arrowhead), N-glycosylated ER/cis-Golgi-localized (arrow 1), non N-glycosylated full-length CLN7 (arrow 2), the 47 kDa form (arrow 3),
the 38 kDa fragment (arrow 4) and the 36 kDa fragment (closed arrowhead) are indicated. Non-speciﬁc bands are indicated by asterisks.
1620 P. Steenhuis et al. / Biochimica et Biophysica Acta 1822 (2012) 1617–1628We next asked whether the 38 kDa and 47 kDa bands also result
from the cleavage of CLN7 by lysosomal cysteine/serine proteases. In
extracts of COS-7 cells incubated in the presence of ammoniumchloride
and treated with PNGase F prior to immunoblotting the intensity of the38 kDa band decreased compared to non-treated cells (Fig. 2C, lane 3).
This suggests that the 38 kDa CLN7 fragment is also generated by pro-
teolytic cleavage. To a lesser extent, treatment of cells with the inhibi-
tors E-64 or leupeptin also resulted in a reduction of the 38 kDa band
1621P. Steenhuis et al. / Biochimica et Biophysica Acta 1822 (2012) 1617–1628(Fig. 2C, lanes 4 and 5). This indicated that cysteine proteases are in-
volved in two cleavage events in CLN7: one that results in a non N-
glycosylated 36 kDa fragment and one that results in an N-
glycosylated fragment with an apparent molecular mass of 38 kDa
after deglycosylation with PNGase F. Incubation of cells with the
aspartic protease inhibitor pepstatin A did not alter the intensity of
the 38 kDa band (Fig. 2C, lanes 6 and 7). Although the 47 kDa band is
difﬁcult to distinguish from the 53 kDa band in Fig. 2C, its intensity
does not change upon treatment with ammonium chloride, E-64,
leupeptin or pepstatin A. This suggests that the 47 kDa band is the prod-
uct of a non-lysosomal cleavage event. Alternatively, it may represent
full-length non N-glycosylated CLN7 and the 53 kDa form may be the
result of an additional post-translational modiﬁcation. In an additional
experiment, COS-7 cells were transfected with 3xFLAG-CLN7 cDNA
and treatedwith NH4Cl or Z-FY-CHO, which inhibits the cysteine prote-
ase cathepsin L [24]. The 36 kDaCLN7 fragment (closed arrowhead) dis-
appeared completely after treatment with either NH4Cl or Z-FY-CHO.
Treatment of cells with NH4Cl resulted in a 40% decrease in the amount
of 38 kDa fragment (Fig. 2D, lane 4), while treatment with Z-FY-CHO
resulted in a 33% decrease (Fig. 2D, lane 6). Overexpression of the N-
glycosylation-defective 3xFLAG-CLN7 N371/376Q [15] resulted in im-
munoreactive bands at 36, 47 and 53 kDa, but not at 38 kDa (Fig. 2D,
lanes 8–11). The 36 kDa band is stronger in 3xFLAG-CLN7 N371/376Q
than in 3xFLAG-CLN7 wild-type and is more sensitive to NH4Cl than
to Z-FY-CHO. Quantitation of proteolytic cleavage showed that the
36 kDa CLN7 fragment comprises 9.5% (±4.3%, n=6) of cellular
CLN7, while the 38 kDa CLN7 fragment comprises 47.3% (±7.1%,
n=6) of cellular CLN7. Therefore, 56.8% of cellular CLN7 polypeptide
is proteolytically cleaved. After the removal of the N-glycosylation
sites the 38 kDa fragment is no longer present and the 36 kDa fragment
comprises 33.9% (±2.2%, n=6) of cellular CLN7, suggesting that N-
glycosylation inhibits the cleavage event that generates the 36 kDa frag-
ment. These results indicate that the 36 kDa and 38 kDa fragments are
proteolytic cleavage products. CLN7 is proteolytically cleaved twice,
once proximal to the N-glycosylation sites in lumenal loop L9 and
once distal to these sites. No conclusions could be drawn about the ori-
gin of the 47 kDa fragment.
To analyze the identity of the C-terminal cleavage fragment, COS-7
cells overexpressing CLN7 with a C-terminal triple Myc tag (CLN7-
3xMyc) were also analyzed (Fig. 2E). Cells expressing CLN7-3xMyc
were incubated in the absence or presence of NH4Cl and total cell ex-
tracts were analyzed by FLAG immunoblotting. Full-length CLN7-
3xMyc and its C-terminal fragmentwere detected as bands with appar-
ent molecular masses of 70–130 kDa (Fig. 2E, open arrowhead) and
20 kDa (Fig. 2E, closed arrowhead), respectively. After PNGase F treat-
ment the molecular mass of full-length CLN7 shifted to 55 kDa (lanes
3 and 4, arrow 2) but the 20 kDa C-terminal fragment was insensitive
to PNGase F indicating that CLN7 is ﬁrst cleaved distal to the two N-
glycosylation sites resulting in a non N-glycosylated C-terminal CLN7
fragment (Fig. 2E, lane 3). Furthermore, cleavage of CLN7-3xMyc
could be inhibited by incubation of the cells in the presence of NH4Cl in-
dicating the cleavage in acidic compartments (Fig. 2E, lane 4). A small
amount of a second fragment of approximately 18 kDa was detected,
which was also sensitive to NH4Cl treatment (Fig. 2E, arrow 5). Quanti-
tation of the immunoreactive band intensities showed that the 20 kDa
CLN7 fragment comprises 27.4% (±10.4%, n=10) of cellular CLN7.
The second, consecutive cleavage event, which occurs proximal to the
two N-glycosylation sites, can only be detected with N-terminally
tagged CLN7 constructs.
To analyzewhether cleavage of CLN7 occurs in the endoplasmic retic-
ulum (ER), COS-7 cells expressing 3xFLAG-CLN7 were incubated in the
presence of brefeldin A (BFA) to inhibit anterograde transport from the
ER to the Golgi apparatus [25]. Treatment of the cells with BFA resulted
in complete disappearance of the 36 kDa immunoreactive band (Fig. 2F,
lane 3, closed arrowhead) as well as an overall reduced signal for CLN7,
possibly reﬂecting inhibition of protein translation due to accumulationof proteins in the ER. As expected, the 57 kDa CLN7 form, representing
CLN7 containing high-mannose and hybrid N-linked oligosaccharides in
the ER and cis-Golgi apparatus (Fig. 2B), disappeared upon PNGase F
treatment accompanied by an increase in the intensity of the non N-
glycosylated CLN7 with an apparent molecular mass of 53 kDa (Fig. 2F,
lane 4). The additional 47 kDaband could also be detected after treatment
of cells with BFA and incubation of cell extracts with PNGase F (Fig. 2F,
lane 4), suggesting that this formof CLN7 is generated in the ER.However,
the 38 kDa band is not visible in these cells, indicating that this form of
CLN7 is generated post-ER. Proteolytic cleavage was also analyzed in
COS-7 cells transfected with mutant 3xFLAG-CLN7 E9A L13A L14A
cDNA, which is partially missorted to the plasma membrane [15]. In
these cells the intensity of the 36 kDa immunoreactive bandwas strongly
decreased (Fig. 2F, lane 5). PNGase F treatment resulted in the appearance
of the 47 and 38 kDa bands, but the intensity of the 38 kDa band was
much weaker than in cells transfected with wild-type 3xFLAG-CLN7
(compare Fig. 2F, lane 6 with Fig. 2D, lane 3), suggesting that some
3xFLAG-CLN7 E9A L13A L14A is correctly targeted to lysosomes. In sum-
mary, after deglycosylation, four forms of CLN7 withmolecular masses of
36, 38, 47 and 53 kDa were detected. The 36 kDa and 38 kDa forms are
products of proteolytic cleavage in acidic organelles, while the 47 kDa
and 53 kDa forms are already present in the ER.
To determine the subcellular localization of the N- and C-terminal
domains, a CLN7 construct with GFP fused to its N terminus and a triple
Myc epitope tag fused to its C terminus (GFP-CLN7-3xMyc) was trans-
fected into COS-7 cells. Localization of the N- and C-terminal domains
was detected by GFP ﬂuorescence and Myc- immunostaining, respec-
tively. Both the N- and C-terminal domains of CLN7 co-localized in
LAMP-1 positive compartments (Fig. 3A, panels c and d, g and h). In
combination with the above ﬁndings, this suggests that the GFP-
CLN7-3xMyc protein is still intact when it reaches the lysosomes
where it is proteolytically cleaved.
To determine if the N- and C-terminal CLN7 fragments interact with
the parental molecule, co-immunoprecipitations were performed.
HEK293 cells were co-transfected with GFP-CLN7 and 3xFLAG-CLN7
or with GFP-CLN7 and CLN7-3xMyc and lysates were submitted to
GFP immunoprecipitation using GFP-TRAP® (Fig. 3B). Both full-length
3xFLAG-CLN7 and CLN7-3xMyc (Fig. 3B, upper panels, lanes 2–4 and
6–8), as well as the N-terminal 3xFLAG-CLN7 fragment (Fig. 3B, upper
panel, lanes 2–4) co-precipitatedwith GFP-CLN7, suggesting an interac-
tion between full-length CLN7 polypeptides and full-length CLN7 and
the N-terminal fragment. A weak binding of full-length CLN7 to the
18 kDa and 20 kDa C-terminal fragments was observed, which became
detectable after longer exposure times (Fig. 3B, upper and middle
panels, lanes 6–8).
3.2. Proteolytic cleavage of CLN7 is mediated by cathepsin L
COS-7 cells overexpressing 3xFLAG-CLN7were treatedwith increas-
ing concentrations (1–50 μM) of the membrane permeable Ctsl inhibi-
tors SID26681509 [26] and Z-FY-CHO [27]. Analysis of total cell
extracts by FLAG immunoblotting revealed that SID26681509 partially
inhibited cleavage of CLN7 in a dosage-dependent manner as shown
by the decreased intensity of the 36 kDa fragment (Fig. 4A, lanes 3–6,
closed arrowhead) whereas Z-FY-CHO almost completely inhibited
cleavage at concentrations of 1 μM or higher (Fig. 4A, lanes 7–10). The
amount of full-length CLN7 also decreased when cells are treated with
SID26681509 or Z-FY-CHO but to a lesser extent than the 36 kDa frag-
ment. This becomes clear when quantitating the amount of the
36 kDa cleavage fragment as a percentage of total CLN7 (Fig. 4A, right
panel). The effect of Ctsl inhibitors on the generation of the 38 kDa frag-
ment was studied by treating cells with SID26681509 and Z-FY-CHO
and incubating the cell lysates with PNGase F prior to FLAG immuno-
blotting (Fig. 4B). Treatment of cells with SID26681509 did not signiﬁ-
cantly decrease the amount of the 38 kDa fragment, whereas Z-FY-
CHO treatment resulted in a reduced intensity of the 38 kDa band at
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was not affected by treatmentwith SID26681509 or Z-FY-CHO (Fig. 4B).
To verify Ctsl-mediated cleavage of CLN7by an independent approach,
CLN7 was expressed in both wild-type (Ctsl(+/+)) and Ctsl-deﬁcient
mouse embryonicﬁbroblasts (Ctsl(−/−)MEF). In extracts from transfected
wild-type MEF both the 55–90 kDa band (open arrowhead) and the
36 kDaCLN7 fragment (closed arrowhead) could be detectedby FLAG im-
munoblotting (Fig. 5A, lanes 1–3). In contrast, in Ctsl(−/−) MEF only the
55–90 kDa full-length CLN7 but not the 36 kDa fragment was observed,
indicating that the absence of Ctsl prevents proteolytic cleavage of CLN7
(Fig. 5A, lanes 4–6). Cleavage of CLN7 expressed in cathepsin B-deﬁcient
(Ctsb(−/−)) MEF was not affected (not shown). Cell lysates were also
treated with PNGase F but, interestingly, the 38 kDa fragment could be
detected both in wild-type and in Ctsl(−/−) MEF (Fig. 5B), suggesting
that Ctsl is not required for the cleavage.Next, we determinedwhether expression of Ctsl could rescue the pro-
teolytic cleavage of CLN7 in Ctsl(−/−) MEF. Ctsl(−/−) MEF were either
mock-transfected or co-transfected with 3xFLAG-CLN7 and murine Ctsl
or 3xFLAG-CLN7 and murine Ctsb cDNA. Co-expression of Ctsl could res-
cue proteolytic cleavage of CLN7 in Ctsl(−/−) MEF (Fig. 5C, lanes 5 and 6),
whereas co-expression of Ctsb cDNA had a smaller effect (Fig. 5C, lanes 3
and4). Therefore,we conclude that the lysosomal cysteine protease Ctsl is
required for generation of the 36 kDa fragment, but not for the formation
of the 38 kDa fragment. No effect of Ctsl overexpression on the amount of
the 38 kDa fragment was observed in Ctsl(−/−) MEF (Fig. 5D).
3.3. Cleavage of CLN7 occurs in luminal loop L9
Based on the apparent molecular masses and N-glycosylation
pattern of the N-terminal cleavage products, we hypothesized that
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observed that the apparent molecular mass of non N-glycosylated
CLN7 is smaller than predicted based on the amino acid composition
[15]. Therefore, we generated C-terminal truncation mutants to fur-
ther conﬁne the predicted cleavage site. Premature stop codons
were inserted proximal to the ﬁrst N-glycosylated asparagine residue,
N371 (CLN7 H370X), at the end of loop L9 (CLN7 H415X) and at the
end of loop L11 (CLN7 R482X) based on the predicted topology of
CLN7 and the identiﬁed N-glycosylation sites [9,15] (Fig. 6A). COS-7
cells were transiently transfected with wild-type and truncated
CLN7 cDNA constructs and total cell extracts were incubated in the
absence or presence of PNGase F followed by FLAG immunoblotting
(Fig. 6B). The electrophoretic mobilities of the 36 kDa N-terminal
CLN7 cleavage product and the truncated CLN7 H370X polypeptide
were comparable (Fig. 6B, lanes 3–5). As expected the electrophoretic
mobility of the CLN7 H370X polypeptide was unchanged after
PNGase F treatment indicating the absence of N-linked oligosaccha-
rides (Fig. 6B, lane 5). In extracts from cells expressing CLN7 H415X
or CLN7 R482X immunoreactive bands with slower electrophoretic
mobility corresponding to molecular masses of 51 kDa and 53 kDa
were detected (Fig. 6B, lanes 6 and 8). After PNGase F treatment of
cell homogenates molecular masses of CLN7 H415X and R482X poly-
peptides shifted to 42 kDa and 40 kDa, respectively, indicating the
presence of N-linked oligosaccharides (Fig. 6B, lanes 7 and 9). Thus,
the 38 kDa CLN7 fragment observed after deglycosylation with
PNGase F is likely generated by proteolytic cleavage between residues
370 and 415 in loop L9 (Fig. 2B). These results suggest that both the36 kDa and the 38 kDa CLN7 fragments are generated by proteolytic
cleavage in lumenal loop L9 of CLN7. The apparent molecular masses
of the full-length and truncated CLN7 polypeptides are shown in the
diagram in Fig. 6A. Both 3xFLAG-CLN7 H370X and 3xFLAG-CLN7
H415X did not co-localize with the lysosomal marker protein cathep-
sin D suggesting their retention in the endoplasmic reticulum (Sup-
plementary material, Fig. S2). Hence no N-terminal cleavage
fragment was observed for CLN7 H415X in Western blot analyses
(Fig. 6B). In contrast, CLN7 R482X was co-localized with cathepsin D
indicating its transport to lysosomes. (Supplementary material, Fig.
S2). However no N-terminal cleavage fragment was observed
(Fig. 6B).
3.4. The CLN7 precursor is gradually cleaved
To examine the half-life of CLN7 and the kinetics of proteolytic
cleavage, a CHX pulse-chase experiment was performed in cells ex-
pressing 3xFLAG-CLN7 or the N-glycosylation mutant 3xFLAG-CLN7
N371/376Q (Fig. 7A). 24 h after the start of transfection, cells were
treated with CHX to inhibit new protein biosynthesis. Cells were
harvested at different time points and total cell extracts were analyzed
by FLAG immunoblotting. The intensities of the 55–90 kDa CLN7 bands
decreased in the presence of CHX during the ﬁrst 24-hour interval,
whereas the intensities of the 36 kDa CLN7 fragment increased
(Fig. 7A, lanes 2–4). An additional 33 kDa immunoreactive band was
detected in cells expressing wild-type (Fig. 7A, lanes 2–5) and non N-
glycosylated CLN7 N371/376Q (Fig. 7A, lanes 6–9). However, after
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decreased (Fig. 7A, lane 5). Similar results were obtained for the N-
glycosylation-defective 3xFLAG-CLN7 N371/376Q mutant, although
the ratio of N-terminal fragment to full-length CLN7 was increased
and cleavage appeared to peak earlier, after 8 h of CHX treatment
(Fig. 7A, lanes 6–9). The cDNA construct 3xFLAG-mucolipin-1
(3xFLAG-ML1) was used as a control coding for a polytopic N-
glycosylated membrane protein which is cleaved in lysosomes
(Fig. 7A, lanes 10–12). During the entire 48-hour CHX-chase the inten-
sity of the full-length ~70 kDa 3xFLAG-ML1 immunoreactive band de-
creased whereas the amount of the N-terminal ~40 kDa cleavage
product increased (Fig. 7A, lanes 10–12). To study the kinetics of prote-
olysis and the stability of the 38 kDa cleavage product, the CHX pulse-
chase experiment was repeated and total cell extracts were incubated
in the absence or presence of PNGase F prior to FLAG Western blotting
(Fig. 7B). Similar to Fig. 7A, the intensities of the 55–90 kDa CLN7
bands initially decreased in the presence of CHX, whereas the intensi-
ties of the 36 kDa CLN7 fragment initially increased. The intensity of
the 38 kDa band observed for 3xFLAG-CLN7 after PNGase F treatment
was most intense after 8 h of CHX treatment (Fig. 7B, lanes 6–10).3.5. CLN7 mutations p.T294K and p.P412L alter proteolytic cleavage
To date 31 different mutations have been identiﬁed in the CLN7/
MFSD8 gene in patients with CLN7 disease [9–13]. To investigate the
impact of mutations on expression and proteolytic cleavage, mutant
CLN7 cDNAs were transiently transfected into COS-7 cells and total
cell extracts were analyzed by Western blotting. Only mutations in
the C-terminal half of the CLN7 protein were selected for thesestudies, which are located in the vicinity of the potential cleavage
site in loop L9 (Fig. 8A). The same immunoreactive bands were ob-
served in extracts from COS-7 cells expressing wild-type and mutant
3xFLAG-CLN7 (Fig. 8B) suggesting correct folding and lysosomal
targeting of mutant CLN7 proteins followed by cleavage in lysosomes.
However, in extracts from cells expressing mutant CLN7 p.T294K the
intensity of a 33 kDa immunoreactive band was increased (Fig. 8B,
lane 3). In addition, the intensity of the 36 kDa fragment in COS-7
cells expressing CLN7 p.P412L was enhanced in comparison with
wild-type CLN7 (Fig. 8B, lane 6). When cells overexpressing mutant
CLN7 p.P412L and p.T294K were treated with the Ctsl inhibitor Z-
FY-CHO the intensities of the 55–90 kDa immunoreactive band were
increased whereas the intensities of the 36 kDa and 33 kDa fragments
were strongly reduced (Supplementary material, Fig. S1B), indicating
that cleavage of mutant CLN7 polypeptides is also mediated by Ctsl.
The p.G310D, p.D368H, p.G429D and p.R465Wmutations did not
signiﬁcantly affect proteolytic cleavage of CLN7 (Fig. 8B, lanes 4, 5, 7
and 8). These results suggest that the p.T294K and p.P412L muta-
tions in CLN7 alter the conformation of lumenal loops L7 and L9, re-
spectively, resulting in increased cleavage. Both wild-type and
mutant 3xFLAG-CLN7-polypeptides were mainly localized in lyso-
somal compartments as shown by co-distribution with the lysosom-
al membrane protein LAMP-1 (Fig. 8C). In agreement with these
ﬁndings, wild-type and mutant CLN7-3xMyc polypeptides co-
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Fig. 7. The CLN7 precursor is gradually cleaved. (A) COS-7 cells were mock-transfected
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transfection, cells were either harvested or incubated in the presence of 100 μg/ml cy-
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separated by SDS-PAGE and analyzed by FLAG immunoblotting. (B) COS-7 cells were
mock-transfected (lanes 1 and 6) or transfected with 3xFLAG-CLN7 cDNA (lanes 2–5
and lanes 7–10). Total cell extracts (50 μg) were incubated in the absence (-; lanes
1–5) or presence of PNGase F (+; lanes 6–10) for 1 h and analyzed byWestern blotting
using anti-FLAG. Positions of full-length CLN7 (open arrowhead), N-glycosylated ER/
cis-Golgi-localized (arrow 1), non N-glycosylated CLN7 (arrow 2), the 47 kDa fragment
(arrow 3), 38 kDa fragment (arrow 4), the N-terminal 36 kDa fragment (closed arrow-
head) and an additional band at 33 kDa (arrow 5) are indicated.
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lysosomal localization was independent of the 3xFLAG epitope tag
(Supplementary material, Fig. S3).
4. Discussion
In the present study we demonstrate that full-length CLN7 is
proteolytically cleaved twice. Expression analyses in the presence
of pharmacological inhibitors of lysosomal acidiﬁcation or of
lysosomal proteases showed that cleavage of CLN7 occurs in acidic
compartments and is mediated by lysosomal cysteine proteases. Fur-
thermore, we demonstrated that correct lysosomal targeting of CLN7
is required for proteolytic cleavage. Retention of CLN7 in the endo-
plasmic reticulum by incubation of the cells with BFA resulted in
complete inhibition of proteolytic cleavage, while mistargeting of
CLN7 to the plasma membrane by mutation of its N-terminal dileucine-
based lysosomal sorting motif resulted in reduction of proteolytic cleav-
age. A comparison of the apparent molecular masses of the N-terminal
CLN7 fragment with truncated CLN7 polypeptides suggested that proteo-
lytic cleavage occurs in lumenal loop L9. Lumenal loop L9 of the human
CLN7 membrane protein is N-glycosylated at positions N371 and N376[15] and is the largest lumenal loop within CLN7, encompassing 58
amino acids, which may favor steric access for proteolytic enzymes in
the lysosomal lumen. It would be of interest to know how the uncleaved
fraction of CLN7 polypeptides is protected from proteolytic cleavage. A
possible explanation is that N-glycosylation of lumenal loop L9 of CLN7
limits the rate of proteolysis as it does for LAMP-1 and LAMP-2 [28]. In-
deed we found increased cleavage generating the 36 kDa fragment in
non N-glycosylated CLN7. Surprisingly, the N-terminal 38 kDa fragment
comprises 47.5% of total cellular CLN7, while the C-terminal 20 kDa frag-
ment only comprises 27.4% of cellular CLN7. Thismay be due to lower sta-
bility of the C-terminal fragment.
It is expected that inhibition of lysosomal acidiﬁcation by ammo-
nium chloride would reduce proteolytic cleavage leading to an in-
crease of full-length CLN7. However, we observed no increased
levels of full-length CLN7 (Fig. 2A, lane 3; Fig. 2D, lanes 4 and 9;
Fig. 2E, lane 4; Fig. S1A, lane 2), suggesting decreased protein expres-
sion in the presence of ammonium chloride. Interestingly, Savalas and
co-workers also observed inhibition of proteolytic cleavage for the ly-
sosomal MFS transporter DIRC2 by ammonium chloride and no con-
comitant increase in the amount of full-length DIRC2 [19]. In
contrast, treatment of the cells with cysteine protease inhibitor E-64
or the cysteine/serine protease inhibitor leupeptin resulted in an inhi-
bition of proteolytic cleavage accompanied by an increased amount of
full-length CLN7.
After the lysosomal transporter DIRC2, CLN7 is the second mem-
ber of the MFS that is found to be proteolytically cleaved [19,29]
and the ﬁrst example of a disease-associated lysosomal membrane
protein that is processed by Ctsl. Furthermore, CLN7 is the ﬁrst mem-
ber of the MFS that appears to interact non-covalently with other
CLN7 polypeptides [17]. We observed a high-afﬁnity interaction be-
tween the N-terminal fragment and full-length CLN7, but a low-
afﬁnity interaction between the C-terminal fragment and full-length
CLN7.
The cycloheximide pulse-chase experiments revealed that CLN7 is
gradually cleaved and that only small amounts of full-length CLN7 re-
main after chase periods of 24 and 48 h. In addition, the presence of
distinct 38 kDa, 36 kDa and 33 kDa CLN7 fragments, which have con-
siderable stability in lysosomes suggests that they do not represent
degradation intermediates. However, the signiﬁcance of proteolytic
cleavage for the biological functions of CLN7 is presently unclear as
the substrates and precise functions of CLN7 are unknown. Although
a small fraction of CLN7 is present at the plasma membrane [15], it
is unlikely that CLN7 exerts its function at the cell surface and that ly-
sosomal targeting and subsequent degradation serve a regulatory
function by inactivating the polypeptide. The CLN7 protein has been
identiﬁed in proteomic analyses of puriﬁed lysosomal membranes
[2,3] and mutations in the CLN7/MFSD8 gene result in a severe lyso-
somal storage disorder suggesting an important role of CLN7 for lyso-
somal biogenesis and function. Interestingly, the promoter region of
the CLN7/MFSD8 gene contains the consensus sequence for recogni-
tion by the transcription factor TFEB, which is important for lysosom-
al biogenesis [30,31]. We therefore assume that CLN7 is a bona ﬁde
lysosomal membrane protein and not a plasma membrane protein.
Proteolytic cleavage of integral lysosomal membrane proteins has
been described as a regulatory event to modulate their biological activ-
ity. For example, the polytopic lysosomal membrane protein heparin
sulfate acetyl-CoA α-glucosaminide N-acetyltransferase (HGSNAT) is
synthesized as an catalytically inactive 77 kDa precursor which is par-
tially cleaved in lysosomes into a 29 kDa N-terminal α- and a 48 kDa
C-terminal β-chain [32]. It was shown that proteolytic cleavage and
intralysosomal oligomerization of HGSNAT are required for functional
activation. Similar to CLN7, the HGSNAT precursor is not completely
processed and is still present even after extended chase times of 48
and 72 h. Limited proteolytic cleavage in lysosomes has also been
reported for the lysosomal membrane proteins LAPTM4a, LAPTM4b
and LAPTM5 [33]. The partial cleavage of HGSNAT, LAPTMs and CLN7
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of enzymatically inactive precursors is rapidly converted into mature
forms upon arrival in lysosomes as described for most of the soluble ly-
sosomal enzymes and for the lysosomal membrane protein lysosomal
acid phosphatase (LAP). LAP is cleaved twice to release its catalytically
active soluble form into the lysosomal lumen [34,35]. Another example
is mucolipin-1 (ML1), a member of the transient receptor potential su-
perfamily, which is deﬁcient in mucolipidosis type IV [36]. Cleavage of
ML1 in the lumenal loop between transmembrane domains 1 and 2 re-
sults in two fragments of approximately 37 kDa and 40 kDa [37].
Kiselyov and co-workers demonstrated that ML1 is functionally
inactivated by Ctsb-mediated cleavage [37].
We ﬁrst tested the possibility that proteolytic cleavage of CLN7 is
mediated by the ubiquitously expressed cysteine protease Ctsl,
which is localized in the lumen of lysosomes and therefore a suitable
candidate protease for cleaving sequences localized in lumenal loop
L9 of CLN7 [38]. Treatment of COS-7 cells with increasing concentra-
tions of the cathepsin L inhibitors SID26681509 and Z-FY-CHO re-
vealed that cathepsin L is involved in the cleavage generating the
36 kDa fragment. In contrast, formation of the 38 kDa fragment
could not be signiﬁcantly inhibited by SID26681509 even at high con-
centrations (50 μM), but was reduced in a dose-dependent manner
by Z-FY-CHO. However, Z-FY-CHO treatment has a greater inhibitory
effect on generation of the 36 kDa fragment than on formation of the
38 kDa fragment (Fig. 4). Z-FY-CHO has a half maximal inhibitory
concentration (IC50) of 0.085 μM for cathepsin B [27] and is therefore
likely to non-speciﬁcally decrease the generation of the 38 kDa frag-
ment by inhibiting other cathepsins such as cathepsin B. To conﬁrm
the role of Ctsl for cleavage of CLN7 by an independent approach, ex-
pression analyses of CLN7 were performed in Ctsb- and Ctsl-deﬁcient
MEF. CLN7 was still cleaved in Ctsb(−/−) MEF, whereas in Ctsl(−/−)
MEF no cleavage to the 36 kDa fragment was observed (Fig. 5). In
contrast, the 38 kDa fragment was generated in both wild-type andCtsl(−/−) MEF. Furthermore, proteolytic cleavage of CLN7 in the
Ctsl(−/−) MEF could be rescued by overexpression of Ctsl, but not by
overexpression of Ctsb. Phenotypic analyses of single and double de-
ﬁcient mice (Ctsl/b(−/−)) have shown that Ctsb and Ctsl can compen-
sate for each other in vivo [38,39]. Our data suggest that Ctsl is
critically involved in the cleavage event generating the 36 kDa
fragment and that the absence of Ctsl in MEF cannot be complemen-
ted by Ctsb. The presence of the 38 kDa fragment in Ctsl(−/−) MEF in
combination with the partial inhibition of its generation by Z-FY-CHO,
most likely by non-speciﬁc inhibition of other lysosomal cysteine pro-
teases, suggests that the cleavage event generating the 38 kDa frag-
ment is independent of Ctsl.
To date, 84 different cysteine proteases are known [40], 11 of which
are lysosomal papain-like cysteine cathepsins [41]. Ctsl is one of the
major cysteine proteases required for bulk degradation and processing
of proteins in lysosomes [42]. Mouse Ctsl represents a well characterized,
ubiquitously expressed lysosomal cysteine endopeptidase, which is syn-
thesized as an inactive proenzyme followed by proteolytic cleavage into
two chains upon arrival in lysosomes [43]. Analyses of Ctsl(−/−) mice re-
vealed thatmouse Ctsl plays a role in the hair cycle [21], epidermal prolif-
eration [21,44], cardiac homeostasis [45], processing of prohormones
[46], glucose metabolism [47] and MHCII-mediated antigen presentation
[48]. Different substrates of Ctsl have been identiﬁed including cytosolic
proteins, lysosomal enzyme precursors, nuclear proteins, prohormones
and proteins of the extracellular matrix [40]. In addition, the membrane
protein Toll-like receptor 9 (TLR9) is proteolytically cleaved by Ctsl in ly-
sosomes upon pathogen exposure releasing a C‐terminal fragmentwhich
is required for TLR9 signaling [49,50].
Mouse and human cells show different cathepsin expression pat-
terns so one must be cautious with directly relating these ﬁndings in
mice to processing in human cells. Most notably, the human genome
encodes for two cathepsin L proteases, namely cathepsin L1 and cathep-
sin V, which is also named cathepsin L2 [38,51]. In addition, there are
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human and mouse cell types, but in our experience both cathepsin L
and cathepsin B are generally highly-expressed in mouse MEF. We
found that cathepsin L plays a role in CLN7 cleavage in primary mouse
embryonic ﬁbroblasts and in the COS-7monkey ﬁbroblast cell line, indi-
cating that the mechanism of CLN7 cleavage is conserved from mice to
primates.
The neuronal ceroid lipofuscinoses are characterized by the accu-
mulation of autoﬂuorescent storage material in lysosomes as well as
selective damage and loss of photoreceptors in the retina and neurons
in selected regions of the brain [5,52]. However, Ctsl deﬁciency in
mice is not associated with these pathological alterations. The pheno-
type of these mice suggests that Ctsl-mediated proteolytic cleavage is
not critically required for the functional activation of CLN7 or that an-
other protease with redundant functions cleaves CLN7 in neuronal
cells. Interestingly, mice that are deﬁcient for both Ctsb and Ctsl
have a typical NCL-like phenotype with lysosomal storage, loss of
neuronal cells and brain atrophy indicating that the presence of
both proteases is essential for lysosomal function and maintenance
of the central nervous system [39,53,54]. Proteolytic cleavage of
CLN7 is presumably reduced in these mice and CLN7 activity en-
hanced if cleavage inactivates the polypeptide (see below).
A direct comparison of the phenotypes of Ctsl/b(−/−) and Cln7(−/−)
mice is not possible as no mouse models for CLN7 disease have been
generated so far [14]. However existingmousemodels of variant late in-
fantile NCLs (vLINCL; Cln5, Cln6, Cln8) have a later disease onset as
compared to Ctsl/b(−/−) mice which display an early onset and rapid
progression of neurodegeneration with death at the age of 2 to
4 weeks [39,52]. The different phenotypes of the vLINCL mouse models
make it unlikely that the neurodegenerative phenotype in Ctsl/b(−/−)
mice is caused by impairment of CLN7 function. One possibility is that
the deﬁciency of the redundant cathepsins B and L results in impaired
lysosomal proteolysis and protein turnover. This hypothesis would be
strengthened by the severe neurodegenerative phenotype of the
Cln10 mouse model deﬁcient in the aspartyl protease cathepsin D,
which mediates protein degradation and activates precursor forms of
proteases [55].
Disease-causing mutations in polytopic lysosomal membrane pro-
teins, such as CLN3 and HGSNAT, are typically retained in the endoplas-
mic reticulum due to misfolding of the proteins [56,57]. However, we
and others have shown that several disease-causing mutations in the
CLN7/MFSD8 gene did not alter subcellular localization of CLN7 in lyso-
somal compartments [9,16], suggesting that these mutations cause al-
terations in protein stability and/or biological function in lysosomes,
rather than retention ofmisfolded CLN7proteins in the endoplasmic re-
ticulum or intracellular missorting. In order to study the effect of CLN7
mutations on proteolytic cleavage of CLN7, we expressed both wild-
type andmutant CLN7 in COS-7 cells and performedWestern blot anal-
yses. We selected mutations localized in lumenal loop L7 (p.T294K), in
lumenal loop L9 (p.D368H and p.P412L) or in the transmembrane do-
mains TM8 (p.G310D), TM10 (p.G429D) and TM11 (p.R465W) of
CLN7. Both mutations located in lumenal loops (p.T294K and p.P412L)
but none of the studied mutations located in transmembrane domains
altered Ctsl-mediated proteolytic cleavage (Fig. 8). These results sug-
gest that selected mutations in lumenal loop L9 or in the adjacent lu-
menal loop L7 alter their conformation rendering them more sensitive
to cleavage.
With one exception, the similar clinical phenotype of CLN7 patients
suggests that all CLN7/MFSD8 mutations result in a complete loss of
CLN7 function [12]. The disease-associated c.103 C>T (p. Arg35X)
mutation causes a truncation of CLN7 after the ﬁrst 34 amino acids
with deletion of all 12 transmembrane domains presumably resulting
in a non-functional protein [11,12]. The clinical manifestation of pa-
tients carrying this mutation is indistinguishable from patients with
the p.T294K and p.P412Lmutations, strongly suggesting that thesemu-
tations also lead to a complete loss of CLN7 function. It is thereforeconceivable that enhanced CLN7 proteolysis of p.T294K and p.P412L
contributes to CLN7 disease. In this case unprocessed CLN7 would be
the functional protein and proteolytic cleavage would inactivate the
protein. The observation that only a fraction (56.8% for both cleavage
events combined) of CLN7 is proteolytically cleaved strengthens the hy-
pothesis that proteolysis inactivates CLN7, possibly providing a regula-
torymechanism to limit the duration of its putative transporter activity.
Although the precise function of CLN7 is unknown its lysosomal lo-
calization and its homologies to the MFS family of transporters suggest
that it represents a lysosomal transporter. Thus, CLN7 disease can be
categorized into the group of lysosomal storage diseases caused by de-
ﬁciencies of lysosomal transporters [4]. As in other NCLs, the storage
material in CLN7 disease contains high amounts of mitochondrial ATP
synthase subunit c [58]. It is unknown whether low molecular weight
metabolites accumulate in lysosomes and therefore no conclusions
can be drawn on the nature of transported CLN7 substrate(s). Sequence
comparisons revealed that CLN7 has homologies with amino acid, lac-
tate, pyruvate, glycerophosphoinositol and hexose transporters in
yeast. Twoof these CLN7 homologues, YCR023C and YBR241C, are local-
ized in vacuolar membranes [59]. Thus, it is possible that accumulation
of monosaccharides, carbohydrate derivatives or amino acids in
lysosomes due to the deﬁciency of CLN7 may lead to an NCL-like
phenotype in patients. Interestingly, loss of the predicted lysosomal
MFS anion/sugar permease benchwarmer in Drosophila melanogaster,
results in an NCL‐like phenotype in ﬂies [60]. Furthermore, mutations
in the MFS transporter sialin, which exports sialic acid from lysosomes
into the cytosol, lead to a lysosomal storage disorder [61].
In summary our data suggest that increased proteolytic cleavage
of CLN7 resulting from mutations in luminal loops may lead to im-
paired function of CLN7 in lysosomes. In addition, the analyzed muta-
tions affecting the sequence of transmembrane domains in CLN7 did
not alter proteolytic cleavage of CLN7 in lysosomes suggesting func-
tional impairment by other mechanisms.
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